Product Description
the most advanced generic is WixelaInhub(previously known as MGR001; Mylan, Inc., Canonsburg, PA), which delivers FP/S from a novel multidose dry powder inhaler (Inhubdevice, previously known as CRC749)
Mechanisms of Action: GR Activator, ADRB2 Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: VIATRIS & KG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Asthma
Phase 1: Chronic Obstructive Pulmonary Disease|Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2015-000463-13 |
2015-000463-13 | P1 |
Completed |
Asthma|Chronic Obstructive Pulmonary Disease |
2015-06-12 |
2022-03-13 |
Treatments |
|
NCT02245672 |
MGR001-3001 | P3 |
Completed |
Asthma |
2015-07-01 |
2022-02-25 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|